MLAB
Mesa Laboratories, Inc. · Healthcare · Medical - Specialties
Momentum inputs (comparable managers):
holder breadth +6.2% ·
share flow -24.3% ·
net new positions +5.9%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 67 | 0 | 2.99M | $297.50M | +4 | −4 |
| Q1 2026 | 70 | 0 | 2.66M | $235.21M | +6 | −6 |
| Q4 2025 | 70 | +2 | 2.73M | $214.06M | +2 | — |
| Q3 2025 | 17 | +1 | 1.54M | $103.48M | +2 | −1 |
| Q2 2025 | 13 | +4 | 1.73M | $163.31M | +4 | — |
| Q1 2025 | 6 | -3 | 383.09K | $45.46M | — | −3 |
| Q4 2024 | 9 | +1 | 400.64K | $52.84M | +1 | — |
| Q3 2024 | 7 | 0 | 174.94K | $22.72M | +1 | −1 |
| Q2 2024 | 7 | — | 189.52K | $16.45M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 388.80K | -50.9% | $26.05M | 0.0% | ▼ Trim | 2 | SEC ↗ ×10 |
| 2 | The Vanguard Group ✦ (passive) | 321.72K | -17.4% | $21.56M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 3 | Morgan Stanley ✦ | 254.97K | — | $17.09M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 4 | Millennium Management ✦ | 133.82K | +131.9% | $8.97M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 127.86K | -7.9% | $8.57M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (passive) | 118.95K | -43.9% | $7.97M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Goldman Sachs Group ✦ | 41.78K | — | $2.80M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Citadel Advisors ✦ | 34.18K | +27.2% | $2.29M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | D. E. Shaw & Co. ✦ | 32.81K | +278.7% | $2.20M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 32.64K | +322.4% | $2.19M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 11 | Marshall Wace ✦ | 14.60K | New | $978,346 | 0.0% | New | 1 | SEC ↗ ×3 |
| 12 | Renaissance Technologies ✦ | 10.90K | -84.0% | $730,409 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 9.62K | New | $644,837 | 0.0% | New | 1 | SEC ↗ |
| 14 | JPMorgan Chase ✦ | 8.64K | — | $579,100 | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 15 | GAMCO Investors ✦ | 8.21K | +109.0% | $550,286 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 4.11K | +7.4% | $276,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | Fidelity (FMR) ✦ | 606 | -79.3% | $40,608 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $978,346 | 0.0% |
| Two Sigma Investments | $644,837 | 0.0% |
Exited
| Wellington Management | $2.12M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 158 holders, 4.82M shares, $424.86M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer · President and CEO · 7.09K sh @ 112.80 · $800,090
Director · 900 sh @ 113.69 · $102,321
Open-market sales (S)
Director · 7.09K sh · $800,090
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology